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INTRODUCTION
Antidepressant prescribing has increased 
substantially across Europe and the US 
since the 1990s.1–4 In Scotland, the majority 
of antidepressants are prescribed by GPs for 
the treatment of depression and although 
prescription volumes have increased 
by 4.7% in 2008/2009,5 the concurrent 
incidence and prevalence of depression 
appears to have remained stable.6,7 The 
rise in antidepressant prescribing has been 
mainly explained by small proportional 
increases of patients receiving long-term 
treatment,7 alongside reductions in the 
number of GP consultations for depression: 
declining by more than half from 2003/2004 
to 2008/2009.6,8
Further clarity is needed in understanding 
the relationship between increased long-
term antidepressant prescribing, the 
reduction in depression consultations 
and antidepressant prescribing growth. 
Although current guidelines recommend 
patients in remission should be reviewed 
every 6 months to assess the need to 
continue medication,9,10 there are no formal 
processes to support general practice 
review of this patient population and the 
effect of GPs conducting their own reviews 
is unknown. 
Concern over increasing rates of 
antidepressant prescribing led the 
Scottish Government in 2007 to set Health 
improvement, Efficiency, Governance, 
Access to services and Treatment (HEAT) 
targets to reduce prescribing.11In response, 
the NHS Greater Glasgow and Clyde 
(NHS GG&C) Health Board committed to 
GPs reviewing long-term antidepressant 
prescribing in four community health and 
care partnerships (CHCPs), as medication 
review demonstrably reduces inappropriate 
prescribing and costs.12–15 NHS GG&C 
also knew that six GP practices had 
higher average prescribed daily doses 
(PDD) of selective serotonin re-uptake 
inhibitors (SSRIs) than reported in current 
literature,4,15–17 therefore PDDs were also 
of interest as SSRIs account for half of all 
antidepressant prescriptions.5
The aim of this study was to review 
general practice patients prescribed the 
same antidepressant for ≥2 years, and 
describe prescribing and management pre 
and post-review. 
METHOD
Setting
In 2009, NHS GG&C consisted of 10 local 
CHCPs which together provide healthcare 
services for a diverse population of 
approximately 1.2 million people across 
a varied geographical area. The review 
process of patients prescribed long-term 
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Abstract
Background 
Antidepressant prescribing continues to rise. 
Contributing factors are increased long-term 
prescribing and possibly the use of higher 
selective serotonin re-uptake inhibitor (SSRI) 
doses.
Aim
To review general practice patients prescribed 
the same antidepressant long-term (≥2 years) 
and evaluate prescribing and management pre 
and post-review.
Design and setting
Prospective observational cohort study using 
routine data from 78 urban general practices, 
Scotland.
Method
All patients prescribed antidepressants 
(excluding amitriptyline) for ≥2 years were 
identified from records November 2009 to March 
2010. GPs selected patients for face-to-face 
review of clinical condition and medication, 
December 2009 to September 2010. Pre- and 
post-review data were collected; average 
antidepressant doses and changes in prescribed 
daily doses were calculated. Onward referral to 
support services was recorded. 
Results
8.6% (33 312/388 656) of all registered patients 
were prescribed an antidepressant, 47.1% 
(15 689) were defined as long-term users and 
2849 (18.2%) were reviewed. 811 (28.5%) patients 
reviewed had a change in antidepressant 
therapy: 7.0% stopped, 12.8% reduced dose, 
5.3% increased dose, and 3.4% changed 
antidepressant, resulting in 9.5% (95% CI = 9.1% 
to 9.8% P<0.001) reduction in prescribed daily 
dose and 8.1% reduction in prescribing costs. 
6.3% were referred onwards, half to NHS Mental 
Health Services. Pre-review SSRI doses were 
10–30% higher than previously reported.
Conclusion
Almost half of all people prescribed 
antidepressants were long-term users. 
Appropriate reductions in prescribing can 
be achieved by reviewing patients. Higher 
SSRI doses may be contributing to current 
antidepressant growth.
Keywords
antidepressant; drug therapy; depression; 
primary care.
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antidepressants was rapidly developed 
by four of the CHCPs serving a highly 
urbanised population within the most 
deprived areas of Scotland18 with a high 
burden of disease and chronic conditions.19 
These four CHCPs were interested in 
reviewing antidepressant prescribing and 
were high volume prescribers by defined 
daily doses (DDDs) per capita from the 
Prescribing and Information System for 
Scotland (PRISMS). PRISMS is a web-
based application providing information for 
all community dispensed prescriptions and 
reports at practice, CHCP, health board, 
and Scotland level.20 DDDs are units of 
measurement defined by the World Health 
Organization as ‘the assumed average 
maintenance dose per day for a drug used 
for its main indication in adults’ and does 
not necessarily reflect the recommended 
or PDD.21 The use of DDDs enables a 
convenient method to compare different 
formulations of medicines and prescribing 
volumes between different organisations. 
PRISMS data and General Register Office 
Scotland22 population statistics were used 
to calculate DDDs per capita, for the year 
to September 2009 for CHCP-1, 2, 3, and 
4 of 46.2, 43.6, 40.9, and 38.9, respectively. 
The average DDDs per capita across all 10 
CHCPs was 37.6 (range 29.5 to 46.2). 
The four CHCPs recruited practices 
between November 2009 and March 2010 
via an invitation letter to participate from 
the CHCP prescribing teams and clinical 
directors. Practices agreed to participate 
by completing and returning opt-in forms.
Patients
Patients prescribed the same 
antidepressant for ≥2 years were 
identified by CHCP support staff using a 
data extraction tool specifically designed, 
developed and piloted to identify this patient 
group from individual General Practice 
Administration System Scotland (GPASS) 
systems. GPASS was the most widely used 
general practice system in NHS GG&C 
at this time. This tool identified patients 
prescribed an antidepressant within the 
previous 3 months and patients prescribed 
the same antidepressant for 2 years or 
more. This duration was chosen as current 
guidelines recommend up to 2 years 
antidepressant treatment for those at risk 
of relapse.9,10 Amitriptyline was excluded 
from the search due to its non-mental 
health uses.23 Duloxetine was included as 
an earlier audit of the data found that 
prescriptions for managing conditions 
other than depression were sparse. 
Patients were excluded if aged <18 years, 
under regular psychiatric care, had a GP 
face-to-face antidepressant review within 
the preceding 6 months, or were on the 
severe mental illness register (practices 
review this group as part of the Quality 
Outcomes Framework [QOF]).
This initiative was primarily intended 
to support GP review of patients’ clinical 
condition and medication, in line with 
current guidelines,9,10 therefore a planned 
sample size for research purposes was 
not calculated. However, it was known that 
patient numbers would be sufficiently high 
to permit analysis of the prescription data. 
Practices were asked to review and submit 
forms for a proportion of all registered 
patients: equivalent to 30 per 4000 patients. 
Other than exclusion criteria, GPs were 
not provided with guidance or a sampling 
framework from which to select patients, 
therefore GPs were allowed to prioritise 
patients for review, permitting flexibility to 
pragmatically select patients they felt may 
benefit most, at the expense of introducing 
selection bias into the study. Reviews 
took place between December 2009 and 
September 2010.
At review GPs completed a standardised 
review form recording: date of review, CHCP, 
practice, name of antidepressant(s), daily 
dose, changes in antidepressant therapy 
and any onward referral. Subsequent 
amendments were made to capture 
patients’ age, sex, GP-defined indication, 
and duration of current antidepressant 
for CHCP-2 to 4. All practices in the four 
CHCPs reviewed patients once and CHCP-
1 followed-up with a second review within 
3 months of the first.
Data handling
Review outcomes were categorised 
as antidepressant continued, stopped, 
reduced, increased or changed. Missing 
outcome data were analysed as though 
patients had continued with pre-
review antidepressant therapy. Where 
How this fits in
Long-term antidepressant prescribing 
is increasing and contributing to the 
overall growth.  There are no formal 
processes to support routine review of 
this patient population in general practice.  
Review of people prescribed long-term 
antidepressants supports optimisation of 
therapy and reductions in prescribing and 
associated costs in certain populations. 
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antidepressant names or daily doses were 
missing it was impossible to ascertain the 
PDD therefore patients were included in 
the analysis as antidepressant continued 
with a PDD of zero milligrams. Where 
combination antidepressants were 
prescribed the PDD of each antidepressant 
was used to calculate the total PDD 
expressed as DDDs. Onward referrals were 
categorised as NHS mental health, NHS 
general medicine, social/council services 
and non-government organisations. Drug 
costs from the British National Formulary 
59 and Scottish Drug Tariff May 2010 were 
used for calculations. Data were collated 
using Microsoft Access® and Excel® and 
further analysed in SPSS (version 19). 
Statistical methods
Statistically significant differences in 
changes in PDD, expressed as DDD pre 
and post-review, were analysed using 
paired two tailed t-test and onward 
referrals to mental health and non-mental 
health services by CHCPs using the c2 test.
 
RESULTS
Eighty-one per cent (78/96) of practices 
agreed to participate, representing 
a total population of 388 656, of whom 
8.6% (33 312/388 656) were prescribed an 
antidepressant, excluding amitriptyline, in 
the last 3 months and 47.1% (15 689/33 312) 
were defined as long-term users.
Seven practices dropped out due to 
practice computer problems, workload 
issues, and undisclosed reasons. Ninety-
one per cent (71/78) of practices agreeing 
to participate reviewed and submitted 
forms for 2849 patients, representing 18.2% 
(2849/15 689) of those prescribed long-
term antidepressants: 1.1% (32/2849) were 
concurrently prescribed two antidepressants 
and 0.1% (1/2849) prescribed three. No 
differences were observed between CHCP 
participating practices (Yates c2 = 3.27, 18 
degrees of freedom [df], P = 0.999), or 
between participating practices and non-
participating practices (Yates c2 = 7.16, 
6 df, P = 0.305). Demographic data were 
available for 94.4% (2691/2849) patients 
reviewed and 67.7% (1929/2849) had 
antidepressant indication recorded (Table 
1). Antidepressant dose information was 
missing for 0.6% (17/2849) of patients.
A total of 28.5% (811/2849) patients had 
a change in antidepressant therapy during 
their face-to-face review: 7.0% (199/2849) 
stopped, 12.8% (366/2849) reduced dose, 
5.3% (150/2849) increased dose, and 
3.4% (96/2849) changed antidepressant 
altogether. This resulted in a 9.5% (95% 
CI = 9.1% to 9.8% P<0.001) reduction in 
mean PDD, expressed as DDDs (Table 2). 
An estimated 8.1% (£23 320 per annum) 
reduction in antidepressant prescribing 
costs were achieved. 
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Table 1. Review patients’ demographics, antidepressant duration 
and indication
Age, years Mean ±SD Median Range 
  All n = 2691 54.4 13.4 54 19–100 
  Female n = 1975 54.8 13.7 54 19–100 
  Male n = 716 53.7 12.4 53 20–87
Duration: same antidepressant (years)     
  All n = 2849a 5.5 3.0 5.0 2.0–24.8 
  Female n = 1975 5.5 3.0 5.0 2.0–24.8 
  Male n = 716 5.5 3.0 4.6 2.0–19.0
Indication for antidepressant n = 1929 % (n) 
  Depression 65.0% (1253) 
  Mixed anxiety depression 22.1% (426) 
  Anxiety disorders 10.1% (194) 
  Other mental health 1.5% (1.5%) 
  General medical 1.4% (27)
a158 patients’ sex not available.
Table 2. Change in prescribed daily doses expressed as defined daily doses (DDDs)
   Pre-review  Post-review
 Number Number of Total %  Mean PDDa Total Mean PDDa Total PDDa 95% CI 
CHCP of patients ADMs prescribed PDDa (SD) PDDa (SD) change % PDDa change P-valueb
CHCP-1 599 618 872.2 1.46 (0.83) 792.7 1.32 (0.89) ↓ 9.3% 8.6 to 10.1 0.007
CHCP-2 485 492 668.8 1.38 (0.73) 629.7 1.30 (0.80) ↓ 5.9% 5.2 to 6.6 0.101
CHCP-3 1039 1041 1333.8 1.28 (0.63) 1203.8 1.16 (0.70) ↓ 9.7% 9.2 to 10.3 <0.001
CHCP-4 726 732 901.7 1.24 (0.67) 793.8 1.09 (0.73) ↓ 12.0% 11.2 to 12.8 <0.001
Total 2849 2883 3776.5 1.33 (0.71) 3419.9 1.20 (0.77) ↓ 9.5% 9.1 to 9.8 <0.001
cCHCP-1 Review 2 525d 525 696.0 1.38 (0.85) 653.6 1.29 (0.89) ↓ 6.1% 5.9 to 7.1 0.006
aPDD expressed DDDs. b95% CI calculated using a two tailed t-test. cCHCP-1: GPs performed two reviews, therefore second review shown separately. dOf the 525 patients 
attending second review: 485 were prescribed one antidepressant, 20 prescribed two antidepressants and 20 prescribed none. ADMs = antidepressant medicines. DDD = 
defined daily dose. PDD = prescribed daily dose. SD = standard deviation. 
There was significant variation between 
CHCPs in patients continuing, stopping, 
reducing, increasing, or changing 
antidepressants (c2 = 30.89, 12 df, P<0.005). 
This was attributable to CHCP-1 having 
fewer patients change antidepressant than 
CHCPs 2, 3 & 4. There was no significant 
difference between CHCPs 2, 3 and 4.
In CHCP-1 87.6% (525/599) patients 
had a second review (Figure 1). This 
resulted in a further 6.1% (95% CI = 5.9% 
to 7.1%, P = 0.006) reduction in PDD and 
an estimated 6.8% (£4346 per annum) 
reduction in prescribing costs. Of the 38 
patients who stopped their antidepressant 
during the first review nine (24%) restarted, 
22 (58%) did not restart and 7 (18%), were 
lost to follow-up. Of the 87 patients who 
reduced dose, 11 (13%) stopped, 34 (39%) 
continued on lower dose, 13 (15%) had a 
further reduction, 11 (13%) increased, 1 
(1%) changed, and 17 (19%) were lost to 
follow-up.
A total of 6.3% (179/ 2849) patients were 
referred onwards to support services: 50.5% 
NHS mental health, 23.1% non-government 
organisations, 14.5% NHS general medical 
and 11.8% social and council services. 
Results were aggregated into NHS mental 
health versus non-mental health services 
(Table 3), finding significant inter-CHCP 
variation (c2 = 10.4, 3 df, P<0.015) with 
CHCP-2 having more referrals to non-
mental health services. There was no 
significant difference between the other 
CHCPs. In comparison to all the other 
practices, practice K reviewed a patient 
group with higher than average SSRI doses 
and appears to have a different pattern of 
change in PDD at review 1 to review 2. More 
data is required to comment further. 
A total of 2883 antidepressants where 
prescribed for the 2849 patients. Pre-
review mean PDDs were calculated for 
each antidepressant (Table 4). For patients 
with a recorded indication of depression 
or mixed anxiety depression, pre-review 
mean (±SD) antidepressant PDDs were 
26.3 mg (±10.2 mg) and 27.0 mg (±12.5 mg) 
for citalopram and fluoxetine, respectively. 
Evidence is lacking for improved citalopram 
or fluoxetine efficacy at doses greater 
than 20 mg daily for the treatment of 
depression.24,25
DISCUSSION
Summary
Almost half of all study patients prescribed 
antidepressants were prescribed the same 
antidepressant long-term. Reviewing long-
term patients resulted in one in four having 
their antidepressant therapy altered, 
providing reductions in prescribing and 
possible associated costs. Where follow-up 
reviews were performed, further additional 
reductions were made.
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Table 3. Onward referral to support services
 CHCP-1 CHCP-2a CHCP-3a CHCP-4 Total
Patient reviews resulting in onward referral, n (%) 27 (4.5) 43 (8.9) 66 (6.3) 43 (5.9) 179 (6.3)
Referrals to services, n (%) 
NHS mental health services 19 (67.8) 15 (31.9) 37 (54.4) 23 (53.5) 94 (50.5)
Non-mental health services 9 (32.1) 32 (68.1) 31 (45.6) 20 (46.5) 92 (49.5)
aSome patients were referred to more than one support service. Mental health services included: community 
mental health teams, primary care mental health teams and community addictions teams. Non-mental health 
services included: NHS general medical clinics (pain, cardiovascular, diabetic, etc), social and council services 
(social services, housing association, Live Active exercise etc) and non-government organisations (Citizens 
Advice, Glasgow Council on Alcohol, Life Link etc).
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Figure 1. CHCP-1 % change in  prescribed 
daily dose (expressed as defined daily dose) 
pre- to post-review.
About 6% of patients were referred 
onwards to support services, with half to 
non-mental health services. There was 
significant variation between CHCPs for 
the type of service category referral, likely 
influenced by geographical location of 
services and service availability. 
The pre-review average PDDs of the 
majority of antidepressants are higher than 
previously reported in literature,4,15–17 with 
SSRI doses 10–30% higher.
Strengths and limitations
This is possibly the largest study reported 
using routine primary patient data to 
quantify changes in antidepressant 
prescribing and management and has an 
advantage over other studies by linking 
patient, antidepressant, PDD, indication 
,and duration of named antidepressant, 
thereby overcoming some limitations 
identified in other studies.4,7,26,27
Medication review has been shown 
to be effective at reducing prescribing 
quantities and costs in general practice.11–14 
The magnitude of observed change in 
PDDs, expressed as DDDs, vary with: 
antidepressant, individual patient, and 
groups of patients reviewed, which is also 
true for observed prescribing costs changes 
that are influenced by the use of proprietary 
medicines, drug tariff prices and patent 
expiry. Although this study was set in highly 
urbanised and deprived areas which may 
have increased the magnitude of observed 
DDD change, the study believes the review 
process itself could be generalised to other 
settings. A more robust health economic 
evaluation would have been beneficial here 
in determining whether cost savings from 
reduced prescriptions were offset by GP 
time in undertaking face-to-face reviews.
The follow-up reviews by CHCP-
1 demonstrated further prescribing 
reductions could be made. However, the 
3-month time period is likely too short 
to assess sustainability of reductions, 
especially as common mental health 
problems are relapsing and remitting in 
nature.9,10 Therefore, a 12-fmonth follow-up 
period with reviews at 3, 6, and 12 months 
would be more appropriate to assess 
long-term sustainability of prescribing 
changes.28 Being a quasi-experimental 
study, the inclusion of a control group or 
any randomisation mechanism was not 
possible and as GPs prioritised which 
patients were reviewed, a positive selection 
bias was likely introduced toward larger 
PDD reductions. In an ideal experimental 
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Table 4. Pre-review mean antidepressant prescribed daily dose and defined daily dose equivalent
 ADMs prescribed,  Mean dose    Mean PDD as DDD (SD) 
 n (%) (N = 2883) (SD) (mg) Range, mg Median, mg Mean PDD as DDD  from literature4,14–16
Fluoxetine 773 (26.8) 28.7 (13.0) 10–60 20 1.43 (0.65) 1.05 [Poluzzi et al 20044] 
      1.07 [Donoghue et al 199614] 
      1.08 [Truter & Kotze16]
Citalopram 744 (25.8) 28.2 (13.8) 4.3–60 20 1.41 (0.69) 1.17 [McManus et al 200315] 
      1.3 [Poluzzi et al 20044] 
      1.2 [Truter & Kotze16]
Paroxetine  250 (8.7) 26.2 (10.5) 5–60 20 1.31 (0.52) 0.90 [Poluzzi et al 20044] 
      1.13 [Donoghue et al 199614] 
      1.15 [McManus et al 200315] 
      1.05 [Truter & Kotze16]
Venlafaxine 210 (7.3) 139.6 (72.2) 18.75–375 150 1.40 (0.72) 1.22 [McManus et al 200315]
Trazodone 194 (6.7) 171.3 (105.0) 50–600 150 0.57 (0.35) 0.30 [Poluzzi et al 20044]
Sertraline 178 (6.2) 94.4 (41.3) 25–200 100 1.89 (0.83) 0.90 [Poluzzi et al 20044] 
      1.60 [Donoghue et al 199614] 
      1.45 [McManus et al 200315]
Mirtazapine 175 (6.1) 35.5 (10.5) 15–60 30 1.18 (0.35) 1.25 [Poluzzi et al 20044]
Dosulepin 145 (5.0) 103.3 (49.0) 25–225 75 0.69 (0.33) 0.51 [Donoghue et al 199614] 
      0.55 [McManus et al 200315]
Escitalopram 70 (2.4) 15.4 (6.5) 5–40 20 1.54 (0.65) 
Lofepramine 61 (2.1) 141.2 (53.9) 70–280 140 1.34 (0.51) 1.28 [Donoghue et al 199614]
Duloxetine 33 (1.1) 65.6 (29.0) 30–120 60 1.09 (0.48) 
Other 50 (1.7) 
ADMs = antidepressant medicines. DDD = defined daily doses. PDD = prescribed daily dose. SD = standard deviation. 
study the study would have developed a 
randomised sampling framework of patients 
on long-term antidepressant medications 
for review. Further, the study cannot rule 
out the possibility that reductions observed 
were a result of the statistical phenomenon 
of regression to the mean, however study 
patients were a stable population of long-
term users and not predicted to get better 
over time, with or without an antidepressant. 
Positive identification of patients’ 
prescribed long-term antidepressants 
helped GPs engage with the review process 
and accommodate the increased workload 
within usual practice constraints. As GPs 
pragmatically selected a sample of patients 
prescribed long-term antidepressants for 
review, it is not possible to confidently infer 
generalisability of results to other patient 
populations, although it is feasible that 
GPs elsewhere may adopt similar criteria 
for patient selection. Using PRISMS it is 
difficult to predict wholesale CHCP level 
prescribing changes as a 9.5% reduction 
in PDDs, expressed as DDDs, equates to 
<1.0% reduction in total CHCP DDDs for 
33 312 patients prescribed antidepressants.
This study established variations in 
antidepressant mean doses by CHCP 
geographical location, which was not 
possible in a previous study.26 As average 
CHCP PDDs follow a similar trend to CHCP 
DDDs per capita, this indicates that regional 
and practice average PDD contribute to 
the variations in antidepressant prescribing 
along with practice and practitioner 
factors.26,29 This study is limited to 4 CHCPs 
which constrains further assessment of this 
observation.
Comparison with existing literature
This study found that 8.6% of registered 
patients were prescribed an antidepressant: 
higher than previously reported in 
a UK study of 6.9% (5648/81 221)30 and 
lower than estimated by NHS Scotland 
Information Services Division 10.4%.5 The 
47.1% of patients prescribed long-term 
antidepressants is comparable with other 
studies of 48%30 and 40.6–51.4%,7 however 
the mean PDD of SSRIs are substantially 
higher than previously reported,4,15–17 
suggesting a tendency to ‘push the dose’ in 
these CHCPs.
The proportion of patients referred to non-
pharmacological services is relatively small. 
As long-term antidepressant users are 
more ‘expert’ in managing their condition, 
conceivably they can make better informed 
choices about personal management 
strategies, be they pharmacological, non-
pharmacological or non-medicalised.31,32
Implications for practice and research
The challenge for clinical practice is 
that increasing numbers of people 
are being prescribed antidepressants 
long-term,7 in spite of consultations for 
depression appearing to reduce8 and 
frequency of antidepressant review 
reducing with therapy duration.33 Use of 
long-term antidepressants for some 
patients may be appropriate to minimise 
relapse.27,34 Although fewer reviews may 
be appropriate for some ‘expert’ patients31 
this is inappropriate for others, such 
as older people with increased risk of 
adverse effects.35 Reviewing continued 
antidepressant therapy provides an 
opportunity to optimise pharmacological 
and non-pharmacological treatment, and 
address repeat prescribing issues.36,37 
The current QOF 2011/2012 supports the 
identification and initial management of 
people with depression38 but not their 
continued care. Future structures, as 
previously called for,39 should consider 
proactive management of depression as 
part of long-term condition management 
strategies. 
SSRIs demonstrate a flat dose 
response curve for the treatment of 
depression,9,10,24,25 meaning prescribing 
doses >20 mg daily citalopram/fluoxetine/
paroxetine or 50 mg daily sertraline is not 
supported by current evidence to provide 
better efficacy.9,10,24,25 Historically GPs 
prescribed subtherapeutic doses of tricyclic 
antidepressants (TCAs)14,15,27 and over the 
years campaigns40 and guidelines9,10,41 have 
supported a message to prescribers to 
increase antidepressant doses to achieve 
better patient response and remission of 
depressive symptoms. This message is 
appropriate for TCAs and venlafaxine whose 
efficacy increases as dose increases,9,10,24,25 
but not for SSRIs where it may be more 
efficacious to change compliant non- and 
poor-SSRI responders to a different SSRI 
rather than increasing the dose.
As increasingly more antidepressants are 
prescribed long-term, more retrospective 
and prospective routine data studies 
are required to assess antidepressant 
long-term safety and efficacy. Further 
opportunities exploiting routine data exist 
in assessing impact of local and national 
prescribing targets, policies and guidelines 
in analyses of linked individual patient 
level prescriptions, PDDs and e-health 
diagnoses data. Lastly, qualitative research 
approaches have a role in explaining why 
GPs may ‘push the dose’. 
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